Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07873827 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study will evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and activity of MEN2312 in participants with hematological malignancies.
Trial Details
NCT Number NCT07873827
Lead Sponsor Stemline Therapeutics, Inc.
Conditions
(from sponsor)		 Hematological Malignancy
Related terms Hematologic Neoplasms, Leukemia, Myeloid, Acute
Enrollment 115 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov